Challenges to antibody therapy in ALL
| 1. Percentage of blasts that express cell surface antigen |
| 2. Density of cell-surface antigen on ALL blast cells |
| 3. Loss of cell-surface antigen expression after antibody-based therapy |
| 4. With many antibody options for R/R ALL (blinatumomab, IO, and CAR T cells), how should the treatments be sequenced? |
| 5. Are antibodies most effective in frontline disease with chemotherapy vs MRD after chemotherapy vs maintenance vs R/R disease? |
| 6. Management of unique antibody-associated toxicities |
| 7. Complexities of antibody administration |
| 8. High costs of antibody therapies |
| 1. Percentage of blasts that express cell surface antigen |
| 2. Density of cell-surface antigen on ALL blast cells |
| 3. Loss of cell-surface antigen expression after antibody-based therapy |
| 4. With many antibody options for R/R ALL (blinatumomab, IO, and CAR T cells), how should the treatments be sequenced? |
| 5. Are antibodies most effective in frontline disease with chemotherapy vs MRD after chemotherapy vs maintenance vs R/R disease? |
| 6. Management of unique antibody-associated toxicities |
| 7. Complexities of antibody administration |
| 8. High costs of antibody therapies |